Despite a modest erosion to fundamentals and sector headwinds, Jefferies does not anticipate any dramatic earnings misses, which could help sentiment continue to turn around.
Ionis Pharmaceuticals led biotech stocks early on Wednesday following a key patent dispute win in the U.S. court system.
Argus reiterated Gilead Sciences as Buy, but hat really matters here is that Argus has a $150 price target on the stock.
Jon C. Ogg The February 29 short interest data have been compared with the previous report, and short interest decreased across the board in these selected biotech stocks.
Here are two big biopharmas, both with multibillion dollar portfolios and both of which have lost a combined $113 billion in market cap since August.
Citigroup came out with a biotech upgrade of sorts on Thursday. The firm issued brand new Buy ratings on four of the largest names within the biotech space.
The February 12 short interest data have been compared with the previous report, and short interest increased across the board in these selected biotech stocks.
It is time to take a look at the 2016 stock buyback kings, those companies that will spend the most buying back their common stock this year alone.
Here are six biotech and pharma stocks that analysts are telling their firm's clients to buy now for solid upside opportunities ahead.
The top analyst upgrades, downgrades and initiations seen on Friday include Activision Blizzard, Boeing, FireEye, Gilead Sciences, Groupon, Netflix and Pandora Media.
The January 29 short interest data have been compared with the previous report, and short interest was mixed in most of the selected biotech stocks.
After Gilead Sciences reported fourth-quarter financial results on Tuesday, analysts weighed in on this biotech giant and in what direction it might go next.
Chris Lange Gilead Sciences reported better-than-expected fourth-quarter financial results after the markets closed on Tuesday.
Chris Lange February 2, 2016: Here are five stocks trading with heavy volume among 209 equities making new 52-week lows today. Tesla Motors Inc. (NASDAQ: TSLA) dropped about 8.5% on Tuesday, posting a new 52-week…
Gilead Sciences is set to release its fourth-quarter earnings report after the markets close on Tuesday.
Chris Lange 
